Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants).~* Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600.~* Patients must have measurable disease defined by RECIST criteria 1.1.~* Tumors in previously irradiated fields may be considered measureable if there is evidence of tumor progression after radiation treatment.~* RAI-refractory disease on structural imaging~* Age ≥ 18 years.~* ECOG performance status ≤ 2~* Patients must have normal organ and marrow function as defined below:~  * Absolute neutrophil count (ANC) \> 1500/mcl~ * Hemoglobin ≥ 9 g/dL~ * Platelets ≥ 100,000/mcl~ * Albumin ≥ 2.5 g/dL~ * Total bilirubin ≤ 1.5x institutional ULN~ * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2x institutional ULN unless it is related to the primary disease~ * Creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) ≥ 50 mL/min OR 24-hour urine creatinine clearance ≥ 50 mL/min~Exclusion Criteria:~* Concomitant malignancies or previous malignancies treated within the past 3 years. Exception: Patients who have been disease-free for 3 years, patients with a history of completely resected non-melanoma skin cancer, and/or patients with indolent secondary malignancies, are eligible.~* Use of other investigational drugs within 28 days preceding the first dose of vemurafenib on this study.~* Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression.~* History or evidence of cardiovascular risk including any of the following:~  * Corrected QT (QTc) interval ≥ 450 msec at baseline or history of congenital long QT syndrome or uncorrectable electrolyte abnormalities. (Patients with well controlled atrial fibrillation are exempt from this criteria.)~ * History of cerebrovascular attack or transient ischemic attack within 6 months prior to the initiation of therapy on this protocol.~ * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination of Vemurafenib and KTN3379 (Type: EXPERIMENTAL): Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).